This approach identified three new compounds with experimentally confirmed SETD2 inhibitory activities, one of which also effectively reduced H3K36me3 levels and blocked the proliferation of the SETD2-dependent AML cell lines. This evidence concerns the gene SETD2 and acute myeloid leukemia.